Amarin Corporation PLC: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Amarin Corporation PLC Unternehmen

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Amarin Corporation PLC Informationen



BörsenkürzelAMRN

Name des UnternehmensAmarin Corporation PLC

IPO-datumApr 01, 1993

CEOMr. Aaron D. Berg

Anzahl der mitarbeiter275

WertpapierartDepository Receipt

GeschäftsjahresendeApr 01

AddresseWeWork One Central Plaza Dame Street

StadtDUBLIN

BörseNASDAQ Capital Market Consolidated

LandIreland

PostleitzahlD02 K7K5

Telefon35316699020

Websitehttps://amarincorp.com/

BörsenkürzelAMRN

IPO-datumApr 01, 1993

CEOMr. Aaron D. Berg

Führungskräfte von Amarin Corporation PLC



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. David Keenan, Ph.D.

Chief Operating Officer, Executive Vice President

7.95K

--

Ms. Diane E. Sullivan

Non-Executive Independent Director

401.00

--

Mr. Oliver O'Connor

Non-Executive Independent Director

401.00

--

Dr. Paul Cohen, M.D.

Non-Executive Independent Director

401.00

--

Ms. Patrice Bonfiglio

Non-Executive Independent Director

--

Mr. Louis Sterling, III

Non-Executive Independent Director

--

Mr. Peter Fishman

Chief Financial Officer

--

Dr. Stephen B. (Steven) Ketchum, Ph.D.

President - Research and Development, Executive Vice President, Chief Scientific Officer

--

Mr. Aaron D. Berg

President, Chief Executive Officer, Director

--

Mr. Keith L. Horn

Non-Executive Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. David Keenan, Ph.D.

Chief Operating Officer, Executive Vice President

7.95K

--

Ms. Diane E. Sullivan

Non-Executive Independent Director

401.00

--

Mr. Oliver O'Connor

Non-Executive Independent Director

401.00

--

Dr. Paul Cohen, M.D.

Non-Executive Independent Director

401.00

--

Ms. Patrice Bonfiglio

Non-Executive Independent Director

--

Mr. Louis Sterling, III

Non-Executive Independent Director

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Sun, Oct 26

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Sarissa Capital Management, L.P.

5.98%

Kynam Capital Management LP

2.77%

Acadian Asset Management LLC

1.16%

Eversept Partners, LP

0.80%

Morgan Stanley & Co. LLC

0.71%

Andere

88.58%

Aktionäre

Anteil

Sarissa Capital Management, L.P.

5.98%

Kynam Capital Management LP

2.77%

Acadian Asset Management LLC

1.16%

Eversept Partners, LP

0.80%

Morgan Stanley & Co. LLC

0.71%

Andere

88.58%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

11.40%

Investment Advisor

2.98%

Investment Advisor/Hedge Fund

1.81%

Research Firm

1.32%

Individual Investor

0.99%

Family Office

0.24%

Foundation

0.18%

Pension Fund

0.09%

Andere

81.00%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

311

3.72M

17.89%

-1.05M

2025Q2

337

3.85M

18.61%

-1.56M

2025Q1

349

5.67M

20.22%

+144.25K

2024Q4

362

81.89M

19.91%

-21.31M

2024Q3

365

76.69M

18.66%

-50.88M

2024Q2

389

87.45M

21.29%

-59.57M

2024Q1

405

98.68M

24.03%

-57.40M

2023Q4

423

103.82M

25.42%

-56.37M

2023Q3

447

95.61M

23.44%

-78.96M

2023Q2

464

107.90M

26.46%

-89.05M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Sarissa Capital Management, L.P.

1.24M

6.01%

-4.00

-0.00%

Jun 30, 2025

Kynam Capital Management LP

576.11K

2.79%

-44.62K

-7.19%

Jun 30, 2025

Acadian Asset Management LLC

241.05K

1.17%

+51.47K

+27.15%

Jun 30, 2025

Eversept Partners, LP

167.28K

0.81%

-2.68K

-1.58%

Jun 30, 2025

Morgan Stanley & Co. LLC

147.27K

0.71%

+31.23K

+26.91%

Jun 30, 2025

SCP Investment, LP

125.00K

0.6%

--

Jun 30, 2025

Longitude (Cayman) Ltd

81.00K

0.39%

-37.50K

-31.65%

Dec 31, 2024

Berg (Aaron D.)

80.71K

0.39%

+36.64K

+83.12%

Jun 26, 2025

WaterFront Wealth, Inc.

94.73K

0.46%

-31.00K

-24.66%

Jun 30, 2025

Two Sigma Investments, LP

76.39K

0.37%

-86.45K

-53.09%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Invesco Nasdaq Biotechnology ETF

0.03%

ProShares Ultra Nasdaq Biotechnology

0.03%

SPDR S&P International Small Cap ETF

0.02%

Global X Aging Population ETF

0%

ActivePassive International Equity ETF

0%

Invesco NASDAQ Future Gen 200 ETF

0%

SPDR Portfolio Developed World ex-US ETF

0%

Invesco Nasdaq Biotechnology ETF

Anteil0.03%

ProShares Ultra Nasdaq Biotechnology

Anteil0.03%

SPDR S&P International Small Cap ETF

Anteil0.02%

Global X Aging Population ETF

Anteil0%

ActivePassive International Equity ETF

Anteil0%

Invesco NASDAQ Future Gen 200 ETF

Anteil0%

SPDR Portfolio Developed World ex-US ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Mar 12, 2025

Merger

20→1

Datum

Art

Verhältnis

Mar 12, 2025

Merger

20→1